Brand Reference: Silenor
| Metric | Verified Benchmark | Source |
|---|---|---|
| Low-Dose Doxepin (3 mg – 6 mg Selective H1 Micro-Dose) RxNorm Concept ID | 3638 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1.8500 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $210.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $18.20 / mo | Cost Plus Drugs Wholesale Feed |
| Community Mean Out-of-Pocket Paid | $22.00 / mo | 24 Zero-PHI Verified Patient Logs |
Exploits pharmacological receptor selectivity scaling: at 3–6 mg (1/25th of antidepressant doses), doxepin binds tuberomammillary H1 wake-promoting receptors exclusively with sub-threshold muscarinic/adrenergic occupancy—preventing 3:00–5:00 AM terminal histamine wake surges with zero anticholinergic hangover.
Across 24 community cost disclosures for Low-Dose Doxepin (3 mg – 6 mg Selective H1 Micro-Dose) (Silenor), cash buyers routing around $210.00 retail markups capture a 91% discount ($18.20/mo benchmark vs $1.8500 NADAC acquisition).
Following administration (3 mg PO 30 min pre-bed (empty stomach)), Low-Dose Doxepin (3 mg – 6 mg Selective H1 Micro-Dose) achieves 29% oral (take >=3 hours after dinner so Tmax aligns with 3 AM nadir) bioavailability and night 1 sleep-maintenance consolidation onset, governed by a 15.3 hours parent / 31 hours nordoxepin terminal half-life through hepatic cyp2c19 and cyp2d6 demethylation.
Before initiating Low-Dose Doxepin (3 mg – 6 mg Selective H1 Micro-Dose) at 3 mg PO 30 min pre-bed (empty stomach), clinical safety checklists rule out untreated narrow-angle glaucoma; severe urinary retention; maoi within 14 days. Logged tolerability patterns center on slight next-hour drowsiness if taken right after heavy meal (12% of reports), mild dry mouth (5% of reports).
Across 24 verified cash-pay logs, Low-Dose Doxepin (3 mg – 6 mg Selective H1 Micro-Dose) achieves a 89.10% Worth-It rating with out-of-pocket spend averaging $22.00/mo versus $210.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 3 mg PO 30 min pre-bed (empty stomach) for Low-Dose Doxepin (3 mg – 6 mg Selective H1 Micro-Dose); monthly out-of-pocket dropped to $16.02 compared with $210.00 retail.
Completed 10 weeks on Low-Dose Doxepin (3 mg – 6 mg Selective H1 Micro-Dose) (6 mg PO 30 min pre-bed). Zero notable side effects on steady dosing.
Consistent biomarker response on 3 mg PO 30 min pre-bed (empty stomach) Low-Dose Doxepin (3 mg – 6 mg Selective H1 Micro-Dose) sourced via Cost Plus Drugs ($21.11/mo cash pay without insurance prior authorization).